Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Go back to Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 17.88 -0.26 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.14 | 52 Week High | $0.19 | |||
| Open | $18.03 | 52 Week Low | $0.07 | |||
| Day High | $18.20 | P/E | N/A | |||
| Day Low | $17.74 | EPS | $-0.01 | |||
| Volume | 1,351,724 | |||||
